These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 20439191)

  • 21. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.
    Bae NC; Chae MH; Lee MH; Kim KM; Lee EB; Kim CH; Park TI; Han SB; Jheon S; Jung TH; Park JY
    Cancer Genet Cytogenet; 2007 Mar; 173(2):107-13. PubMed ID: 17321325
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinicopathological and molecular evidence indicating the independence of bronchioloalveolar components from other subtypes of human peripheral lung adenocarcinoma.
    Koga T; Hashimoto S; Sugio K; Yoshino I; Mojtahedzadeh S; Matsuo Y; Yonemitsu Y; Sugimachi K; Sueishi K
    Clin Cancer Res; 2001 Jun; 7(6):1730-8. PubMed ID: 11410513
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epidermal growth factor receptor mutations in multicentric lung adenocarcinomas and atypical adenomatous hyperplasias.
    Ikeda K; Nomori H; Ohba Y; Shibata H; Mori T; Honda Y; Iyama K; Kobayashi T
    J Thorac Oncol; 2008 May; 3(5):467-71. PubMed ID: 18448997
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel germline mutation: EGFR V843I in patient with multiple lung adenocarcinomas and family members with lung cancer.
    Ikeda K; Nomori H; Mori T; Sasaki J; Kobayashi T
    Ann Thorac Surg; 2008 Apr; 85(4):1430-2. PubMed ID: 18355544
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clustered genomic alterations in chromosome 7p dictate outcomes and targeted treatment responses of lung adenocarcinoma with EGFR-activating mutations.
    Yuan S; Yu SL; Chen HY; Hsu YC; Su KY; Chen HW; Chen CY; Yu CJ; Shih JY; Chang YL; Cheng CL; Hsu CP; Hsia JY; Lin CY; Wu G; Liu CH; Wang CD; Yang KC; Chen YW; Lai YL; Hsu CC; Lin TC; Yang TY; Chen KC; Hsu KH; Chen JJ; Chang GC; Li KC; Yang PC
    J Clin Oncol; 2011 Sep; 29(25):3435-42. PubMed ID: 21810691
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases.
    Schmid K; Oehl N; Wrba F; Pirker R; Pirker C; Filipits M
    Clin Cancer Res; 2009 Jul; 15(14):4554-60. PubMed ID: 19584155
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chromosomal imbalances in lung adenocarcinomas with or without mutations in the epidermal growth factor receptor gene.
    Fong Y; Lin YS; Liou CP; Li CF; Tzeng CC
    Respirology; 2010 May; 15(4):700-5. PubMed ID: 20409020
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Non-BAC component but not epidermal growth factor receptor gene mutation is associated with poor outcomes in small adenocarcinoma of the lung.
    Kobayashi N; Toyooka S; Ichimura K; Soh J; Yamamoto H; Matsuo K; Otani H; Jida M; Kubo T; Tsukuda K; Kiura K; Sano Y; Date H
    J Thorac Oncol; 2008 Jul; 3(7):704-10. PubMed ID: 18594314
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Molecular changes of epidermal growth factor receptor (EGFR) and KRAS and their impact on the clinical outcomes in surgically resected adenocarcinoma of the lung.
    Kim YT; Kim TY; Lee DS; Park SJ; Park JY; Seo SJ; Choi HS; Kang HJ; Hahn S; Kang CH; Sung SW; Kim JH
    Lung Cancer; 2008 Jan; 59(1):111-8. PubMed ID: 17904685
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas.
    Taniguchi K; Uchida J; Nishino K; Kumagai T; Okuyama T; Okami J; Higashiyama M; Kodama K; Imamura F; Kato K
    Clin Cancer Res; 2011 Dec; 17(24):7808-15. PubMed ID: 21976538
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Abnormalities of epidermal growth factor receptor in lung squamous-cell carcinomas, adenosquamous carcinomas, and large-cell carcinomas: tyrosine kinase domain mutations are not rare in tumors with an adenocarcinoma component.
    Ohtsuka K; Ohnishi H; Fujiwara M; Kishino T; Matsushima S; Furuyashiki G; Takei H; Koshiishi Y; Goya T; Watanabe T
    Cancer; 2007 Feb; 109(4):741-50. PubMed ID: 17238183
    [TBL] [Abstract][Full Text] [Related]  

  • 32. EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients.
    Tang X; Shigematsu H; Bekele BN; Roth JA; Minna JD; Hong WK; Gazdar AF; Wistuba II
    Cancer Res; 2005 Sep; 65(17):7568-72. PubMed ID: 16140919
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNA methylation in small lung adenocarcinoma with bronchioloalveolar carcinoma components.
    Kubo T; Yamamoto H; Ichimura K; Jida M; Hayashi T; Otani H; Tsukuda K; Sano Y; Kiura K; Toyooka S
    Lung Cancer; 2009 Sep; 65(3):328-32. PubMed ID: 19144441
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidermal growth factor receptor mutations in small cell lung cancer.
    Tatematsu A; Shimizu J; Murakami Y; Horio Y; Nakamura S; Hida T; Mitsudomi T; Yatabe Y
    Clin Cancer Res; 2008 Oct; 14(19):6092-6. PubMed ID: 18829487
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer.
    Chou TY; Chiu CH; Li LH; Hsiao CY; Tzen CY; Chang KT; Chen YM; Perng RP; Tsai SF; Tsai CM
    Clin Cancer Res; 2005 May; 11(10):3750-7. PubMed ID: 15897572
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Different epidermal growth factor receptor gene mutations in a patient with 2 synchronous lung cancers.
    Nakano H; Soda H; Nakamura Y; Uchida K; Takasu M; Nakatomi K; Izumikawa K; Hayashi T; Nagayasu T; Tsukamoto K; Kohno S
    Clin Lung Cancer; 2007 Nov; 8(9):562-4. PubMed ID: 18186961
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Non-mucinous and mucinous subtypes of adenocarcinoma with bronchioloalveolar carcinoma features differ by biomarker expression and in the response to gefitinib.
    Wislez M; Antoine M; Baudrin L; Poulot V; Neuville A; Pradere M; Longchampt E; Isaac-Sibille S; Lebitasy MP; Cadranel J
    Lung Cancer; 2010 May; 68(2):185-91. PubMed ID: 19581016
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bronchioloalveolar carcinoma: the case for two diseases.
    Garfield DH; Cadranel J; West HL
    Clin Lung Cancer; 2008 Jan; 9(1):24-9. PubMed ID: 18282354
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gene amplification and protein expression of EGFR and HER2 by chromogenic in situ hybridisation and immunohistochemistry in atypical adenomatous hyperplasia and adenocarcinoma of the lung.
    Awaya H; Takeshima Y; Furonaka O; Kohno N; Inai K
    J Clin Pathol; 2005 Oct; 58(10):1076-80. PubMed ID: 16189154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathological features of lung adenocarcinoma with KRAS mutations.
    Kakegawa S; Shimizu K; Sugano M; Miyamae Y; Kaira K; Araki T; Nakano T; Kamiyoshihara M; Kawashima O; Takeyoshi I
    Cancer; 2011 Sep; 117(18):4257-66. PubMed ID: 21387273
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.